Entries by Sommer Aweidah


Vuja De Sciences Announces the Appointment of Two New Board Members

New members bring unparalleled scientific and clinical expertise to anti-metastasis approaches in osteosarcoma and cancer in general, for both human and veterinary settings. HOBOKEN, N.J. (PRWEB) January 07, 2020 – Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence, today announced the appointments of […]


Ethos Discovery Receives Support from Citizens Bank

Woburn, Mass. — November 1, 2019: Ethos Discovery is excited to announce a $5,000 grant received by Citizens Bank in support of the Ethos Discovery Research program. This contribution will help Ethos Discovery continue its work to improve health outcomes for humans and animals with complex medical problems. Ethos Discovery is a 501(c)(3) nonprofit that […]


Ethos Discovery Launches Collaborative Program to Cure Canine Hemangiosarcoma

Woburn, MA –  August 27, 2019:  Ethos Discovery recently announced its plan to deliver curative outcomes for dogs with splenic hemangiosarcoma. This will be achieved through a combination of genomic and precision medicine, and aligned prospective clinical trials collectively named ePUSH (Ethos Precision Medicine Umbrella Study for Hemangiosarcoma). Ethos Veterinary Health (Ethos) just opened the […]


LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

Source: LexaGene Holdings Inc BEVERLY, Mass., June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of […]


New study boasts 90% accuracy when using PARR to diagnose canine lymphoma

Article originally published in NEWStat, an American Animal Hospital Association Publication  Written by Tony McReynolds Who measures the measurements? Who diagnoses the diagnostics? In short, who assays the assays? Veterinarians have been using polymerase chain reaction for antigen receptor rearrangement (PARR), a readily available molecular assay that helps diagnose some kinds of canine lymphoma, for years. […]

, , , ,

TGEN-Ethos Study Underscores Need for Setting High Standards in Veterinary Cancer Diagnostics

Written by Steve Yozwiak PHOENIX, Ariz. — May 21, 2019 — Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, announced today that they have developed a highly accurate test for the diagnosis of canine lymphoma. In a study published in the Journal of Veterinary Internal […]


Nationwide, Multi-center, Prospective Study of Canine Splenic Hemangiosarcoma Complete

Cutting Edge Cancer Research in Veterinary Specialty Practice: Ethos Veterinary Health Completes First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma Woburn, Mass. — Jan. 15, 2019 — Ethos Veterinary Health(Ethos) has completed the patient accrual phase of their new Canine Hemangiosarcoma Molecular Profiling (CHAMP) study. Hemangiosarcoma is one of the most malignant forms of cancer in […]


Development Collaboration to Prevent Cancer Recurrence

First-Ever Human Health and Animal Health Drug Development Collaboration to Prevent Cancer Recurrence Ethos Veterinary Health and Vuja De Sciences to utilize novel cellular assays of cancer metastasis and integration of pet dogs with cancer to empower innovative metastasis-focused drug development collaboration. WOBURN, MASS. AND HOBOKEN, N.J. (PRWEB) DECEMBER 18, 2018 Ethos Veterinary Health (“Ethos”) […]